Intellia Therapeutics, Inc. (NTLA) compared with its closest peers (BEAM, EDIT, IONS, MGX, DTIL). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Beam Therapeutics and Ionis Pharmaceuticals: named as a competitor in the 10-K; Editas Medicine, Metagenomi Therapeutics and Precision BioSciences: names this company as a competitor in its 10-K.
| Company | Market Cap | P/E |
|---|---|---|
| Beam Therapeutics Inc. (BEAM) | $2.48B | — |
| Editas Medicine, Inc. (EDIT) | $416.97M | — |
| Ionis Pharmaceuticals, Inc. (IONS) | $9.00B | — |
| Metagenomi Therapeutics, Inc. (MGX) | $43.82M | — |
| Precision BioSciences, Inc. (DTIL) | $198.46M | — |
| MeiraGTx Holdings plc (MGTX) | $1.23B | 15.6 |
| BridgeBio Pharma, Inc. (BBIO) | $14.17B | — |
| Kura Oncology, Inc. (KURA) | $1.01B | — |
| Enanta Pharmaceuticals, Inc. (ENTA) | $377.47M | — |
| Kymera Therapeutics, Inc. (KYMR) | $9.56B | — |
| Sector P/E (Healthcare) | 19.4 |
| Industry P/E (Pharmaceutical Products) | 15.1 |
NTLA overview · NTLA earnings · NTLA financials · NTLA KPIs · NTLA documents · NTLA ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.